• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ICU Medical touts dosing errors study

February 15, 2017 By Sarah Faulkner

ICU Medical touts dosing errors studyICU Medical (NSDQ:ICUI) said today that a multi-hospital study showed improvements in potentially catastrophic dosing errors and drug library compliance when its Plum infusion pumps and Hospira (NYSE:HSP) MedNet safety software were integrated with the hospitals’ electronic medical records.

The rate of potentially catastrophic dosing errors fell by 52% after smart-pump EMR integration, the study found, and compliance with a participating hospital’s drug libraries increased by 156%, on average.

One hospital found that the rate of potentially catastrophic dosing errors fell by as much as 73%.

The study, which was performed at 3 community hospitals in the U.S., integrated a Cerner Millennium EMR with ICU Medical’s Plum smart infusion system and Hospira MedNet safety software. The study’s 3 metrics – incidence rate, variability of severity and compliance – improved at each hospital following integration.

“Both the reduced range of variance of PCDEs and the narrower confidence intervals in the post integration data demonstrate that variability in programming is greatly reduced after integration,” study author Valerie King said in prepared remarks. “Successful integration of infusion devices and hospitals’ EMR enables healthcare providers to ensure the ‘5 Rights’ verification—right patient, medication, dose, time and route.”

This month, ICU Medical closed its $900 million buy of the Hospira infusion pump business from Pfizer (NYSE:PFE), confirming rumors that the drug giant was looking to sell the business.

The deal was scaled back from $1 billion and called for ICU Medical to offer 3.2 million new shares, or $419.3 million, and $275 million in cash, along with an additional $225 million contingent upon performance milestones through the end of 2019.

The transaction brings Hospira’s infusion systems business, including IV pumps, solutions, disposables and other assets to ICU Medical, while Pfizer will hold a 16.6% stake in ICU.

Filed Under: Featured, Hospital Care, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Hospira Inc., ICU Medical, Pfizer Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS